ClinicalTrials.gg
CompletedNCT03378076Updated Jan 24, 2024Results posted

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

A Phase 2 interventional study of FX006 32 mg and TAcs 40 mg in Bilateral Knee Osteoarthritis, sponsored by Pacira Pharmaceuticals, Inc. Completed at 3 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-01-24.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies testing FX006 in Osteoarthritis — none open to participants now, none under way, none of them phase 3. FX006 · Osteoarthritis.

Enrollment
11th of 15
24 · median 55
Started
2017
with 2 others
Phase 2
11 of 15
none open now
Registered
11th of 15
by date
Lead sponsor
15 of 15
Pacira Pharmaceuticals, Inc

Among the 15 studies testing FX006 in Osteoarthritis, this one is the 11th largest by enrollment, is one of 3 that started in 2017, is one of 11 in phase 2, and was the 11th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 15 studies testing FX006 in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →

About FX006

FX006: first FDA approval 1957 (ARISTOCORT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing FX006 in Osteoarthritis as a file.
02

Study summary

This is a randomized, open-label, parallel group study to compare systemic exposure of triamcinolone acetonide following administration into both knees of either FX006 or TAcs.

Read the detailed description

This is a randomized, open label, parallel group study that will be conducted in male and female patients ≥ 40 years of age with bilateral knee OA.

Approximately 24 patients will be randomized to one of two treatment groups (1:1) and treated with IA injections to both knees of either:

  • extended-release FX006 64 mg total dose (approximately 12 patients) or
  • immediate-release TAcs 80 mg total dose (approximately 12 patients) Each patient will be screened to confirm the diagnosis of OA and eligibility based on the inclusion/exclusion requirements and will be randomized to treatment on Day 1. Following screening, pharmacokinetics (PK) and safety will be evaluated at 6 out-patient visits scheduled on Study Days 1 [calendar day of injection], 2, 8, 15, 29, and 43.
03

Conditions studied

  • Bilateral Knee Osteoarthritis

Keywords

  • Osteoarthritis
  • Knee
  • Corticosteroid
  • Bilateral
  • Pain
  • Intra-articular
  • Injection
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consent to participate in the study
  • Male or female greater than or equal to 40 years of age
  • Symptoms consistent with OA in both knees for greater than or equal to 6 months prior to Screening (patient reported is acceptable)
  • Currently meets ACR Criteria (clinical and radiological) for OA in both knees
  • Knee pain in both knees for greater than 15 days over the last month (as reported by the patient)
  • (BMI) less than or equal to 40 kg/m2
  • Morning serum cortisol result within normal range at Screening (5-23 mcg/dL or 138-635 nmol/dL)
  • Ambulatory and in good general health
  • Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions.
  • Willing to abstain from use of protocol-restricted medications during the study

Exclusion criteria

Exclusion Criteria:

  • Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
  • History of infection in either knee joint
  • Clinical signs and symptoms of active knee infection or crystal disease in either knee within 1 month of Screening
  • Unstable joint (such as a torn anterior cruciate ligament) in either knee within 12 months of Screening
  • Presence of surgical hardware or other foreign body in either knee
  • Surgery or arthroscopy of either knee within 12 months of Screening
  • IA treatment of any joint with any of the following agents within six (6) months of Screening: any preparation ( or marketed, including FX006), any biologic agent (e.g., rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed).
  • IA treatment in either knee with hyaluronic acid (investigational or marketed) within 6 months of Screening
  • Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening
  • Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
  • Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    FX006 32 mg

    Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)

    Drug: FX006 32 mg

  • Active comparator
    TAcs 40 mg

    Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)

    Drug: TAcs 40 mg

Interventions

  • Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)

    Also known as: Zilretta

  • Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)

    Also known as: Kenalog®-40 Injection, Triamcinolone Acetonide Crystalline Suspension (TAcs), TCA-IR 40

06

What researchers measure

Primary outcomes

  1. Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma

    Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma. For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations

    Time frame: 43 days

  2. Incidence of Treatment Emergent Adverse Events

    Safety analyses were conducted using the safety population. Analyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).

    Time frame: 43 days

07

Results

Posted May 1, 2019

Participant flow

Participant flow — Overall Study
MilestoneFX006 32 mgTAcs IR 40 mg
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryMeasure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma

Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma. For the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations

Time frame:
43 days
Reported as:
Geometric mean · pg/mL
Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma
pg/mLFX006 32 mgTAcs 40 mg
Day 1- Hour 11801.5 (1261.50 to 2572.77)4507.9 (1205.43 to 16857.74)
Day 1 - Hour 21893.6 (1328.58 to 2698.84)5140.1 (1327.67 to 19899.79)
Day 1 - Hour 31958.1 (1336.54 to 2868.86)5443.8 (1357.81 to 21825.90)
Day 1 - Hour 42013.8 (1381.39 to 2935.59)5454.2 (1409.98 to 21098.36)
Day 1 - Hour 51914.4 (1291.93 to 2836.82)5338.9 (1366.93 to 20852.59)
Day 1 - Hour 61900.2 (1293.77 to 2790.96)5430.6 (1442.24 to 20448.57)
Day 1 - Hour 81928.1 (1288.45 to 2885.17)5199.0 (1418.52 to 19054.80)
Day 1 - Hour 101839.8 (1241.72 to 2725.96)4948.8 (1392.07 to 17593.31)
Day 1 - Hour 121793.9 (1247.06 to 2580.66)4507.8 (1294.51 to 15697.14)
Day 2 - Hour 241948.8 (1349.93 to 2813.36)4185.4 (1614.39 to 10850.75)
Day 81397.0 (1073.13 to 1818.65)450.8 (230.66 to 880.92)
Day 15956.2 (759.23 to 1204.25)428.7 (231.92 to 792.29)
Day 29445.8 (313.12 to 634.80)334.6 (182.45 to 613.80)
Day 43265.8 (199.56 to 354.03)241.0 (119.11 to 487.54)
PrimaryIncidence of Treatment Emergent Adverse Events

Safety analyses were conducted using the safety population. Analyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).

Time frame:
43 days
Reported as:
Number · participants
Incidence of Treatment Emergent Adverse Events
participantsFX006 32 mgTAcs 40 mg
Patients with TEAE Grade 163
Patients with TEAE Grade 212
Patients with TEAE Grade 310
Patients with TEAE Grade 400
Patients with TEAE Grade 500

Adverse events

Collected over Adverse Events were collected following IA administration through the final study visit at 43 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FX006 32 mg0/12 (0%)0/12 (0%)8/12 (66.7%)
TAcs 40 mg0/12 (0%)0/12 (0%)5/12 (41.7%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventFX006 32 mgTAcs 40 mg
BronchitisInfections and infestations2/120/12
ArthralgiaMusculoskeletal and connective tissue disorders0/122/12
HaemorrhoidsGastrointestinal disorders0/121/12
VomitingGastrointestinal disorders1/120/12
FatigueGeneral disorders0/121/12
Injection Site PainGeneral disorders1/120/12
Vessel Puncture Site HaematomaGeneral disorders1/120/12
Food AllergyImmune system disorders0/121/12
NasopharyngitisInfections and infestations1/120/12
SinusitisInfections and infestations0/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)FX006 64 mgTAcs IR 80mgTotal
Mean61.8 ± 6.4561.6 ± 8.1761.7 ± 7.20
Sex: Female, Male
Sex: Female, Male(Participants)FX006 64 mgTAcs IR 80mgTotal
Female10919
Male235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FX006 64 mgTAcs IR 80mgTotal
Hispanic or Latino202
Not Hispanic or Latino101222
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FX006 64 mgTAcs IR 80mgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American224
White101020
More than one race000
Unknown or Not Reported000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)FX006 64 mgTAcs IR 80mgTotal
Mean33.31 ± 3.66930.35 ± 4.95531.83 ± 4.524
08

Study locations

3 sites
  • LA Biomed at Harbor-UCLA Medical Center
    Torrance, California 90509, United States
  • Rochester Clinical Research
    Rochester, New York 14609, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
09

References and documents

Publications

  • Kivitz A, Kwong L, Shlotzhauer T, Lufkin J, Cinar A, Kelley S. A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis. Ther Adv Musculoskelet Dis. 2019 Oct 16;11:1759720X19881309. doi: 10.1177/1759720X19881309. eCollection 2019. PubMed 31662801 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Mar 2018, 3 months.

Results were first posted in May 2019, 1 year 1 month after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 3 months is below that.

Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2017
First posted
Dec 19, 2017
StartActual
Dec 6, 2017
Primary completionActual
Mar 14, 2018
CompletionActual
Mar 14, 2018
Results first posted
May 1, 2019
Last update
Jan 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03378076
Responsible party
Sponsor
First posted
Dec 19, 2017
Start date
Dec 6, 2017
Primary completion
Mar 14, 2018
Completion
Mar 14, 2018
Results posted
May 1, 2019
Last update
Jan 24, 2024

Study contacts

Scott Kelley, MD
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FX006

Start the discussion